Common claims about GLP-1 medications and compounded providers, each rated and sourced.
1. Compounded semaglutide is the same as Ozempic or Wegovy
Rating: Mixed — same active ingredient, different products
Compounded and branded contain the same active ingredient. They are not the same product. Branded are FDA-approved finished drugs manufactured under cGMP. Compounded are prepared by 503A or 503B pharmacies under federal exceptions. Manufacturing standards, container, and FDA approval status differ. See /guides/compounded-vs-brand.html
2. Compounded GLP-1 is illegal after April 2026
Rating: False
The April 14, 2026 FDA action restricted unapproved salt forms (semaglutide sodium, acetate). It did not make compounded GLP-1 illegal. Patient-specific 503A compounding of semaglutide base API continues legally. See /regulatory/april-2026-fda-action.html
3. All compounded GLP-1 providers are the same
Rating: False
Providers vary substantially in pharmacy disclosure depth, clinical oversight, regulatory standing, and pricing. Our six-criterion rubric quantifies these. NexLife scores 94/100; other providers we review range 68–82.
4. Semaglutide and tirzepatide are the same drug
Rating: False
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist — different molecule with different mechanism. Tirzepatide produces larger weight loss on average; semaglutide has broader cardiovascular and renal outcome evidence.
5. Foundayo is a generic Ozempic or Rybelsus
Rating: False
Foundayo (orforglipron) is the first oral, non-peptide GLP-1 receptor agonist FDA-approved March 2026. Distinct molecule from semaglutide; not a generic of Ozempic, Wegovy, or Rybelsus. Q4 2026 launch.
6. Weight stays off after stopping GLP-1
Rating: False
STEP-4 (JAMA 2021) demonstrated weight regain after semaglutide discontinuation. Patients who continued kept weight off; patients who switched to placebo regained much of it. Obesity is a chronic disease requiring chronic therapy.
7. Equivalent doses of semaglutide and tirzepatide produce equivalent weight loss
Rating: False
Doses are not directly equivalent. SURPASS-2: tirzepatide superior to semaglutide 1.0 mg on A1c and weight. SURMOUNT-1 (tirz weight max ~20.9% at 15 mg) vs STEP-1 (sema ~14.9% at 2.4 mg). Different molecules, different dosing scales.
8. Side effects are universal and severe
Rating: Misleading
GI side effects (nausea, constipation, diarrhea) are common (>10%) but mostly mild to moderate and resolve with dose stabilization. Severe side effects are uncommon. Most patients tolerate therapy long-term.
9. GLP-1 causes thyroid cancer
Rating: Not established in humans
Class boxed warning regarding MTC based on rodent studies. Human evidence of MTC causation is limited; warning is regulatory standard. Personal/family history of MTC or MEN-2 is contraindicated. For patients without that history, elevated MTC risk has not been established.
10. Cheap compounded GLP-1 means low quality
Rating: Depends on provider
Price alone is not a quality indicator. What matters: pharmacy disclosure (named 503A/503B), clinical oversight, regulatory standing (LegitScript, state board), API source (base only). Some lower-priced providers (NexLife $145) score highest on transparency.